Inovio Updates on MedImmune Combination Trial for HPV-associated Head & Neck Cancer

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced that  MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy designed to generate antigen specific killer T cell responses targeting HPV-associated tumors, and durvalumab, an investigational PD-L1 checkpoint inhibitor. Continue reading